Amyotrophic Lateral Sclerosis - Pipeline Review, H2 2017

Date: October 31, 2017
Pages: 478
Price:
US$ 2,000.00
License [?]:
Publisher: Global Markets Direct
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: A55886D8500EN
Leaflet:

Download PDF Leaflet

Amyotrophic Lateral Sclerosis - Pipeline Review, H2 2017
Amyotrophic Lateral Sclerosis - Pipeline Review, H2 2017

SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Amyotrophic Lateral Sclerosis - Pipeline Review, H2 2017, provides an overview of the Amyotrophic Lateral Sclerosis (Central Nervous System) pipeline landscape.

Amyotrophic lateral sclerosis (ALS) is the most common degenerative disease of the motor neuron system. The disorder is named for its underlying pathophysiology, with amyotrophy referring to the atrophy of muscle fibers, which are denervated as their corresponding anterior horn cells degenerate. Lateral sclerosis refers to the changes seen in the lateral columns of the spinal cord as upper motor neuron (UMN) axons in these areas degenerate and are replaced by fibrous astrocytes (gliosis). Symptoms include difficulty breathing, difficulty swallowing, head drop due to weakness of the neck muscles, muscle cramps, speech problems, such as a slow or abnormal speech pattern (slurring of words), voice changes, hoarseness, weight loss.

REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Amyotrophic Lateral Sclerosis - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Amyotrophic Lateral Sclerosis (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Amyotrophic Lateral Sclerosis (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Amyotrophic Lateral Sclerosis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 2, 1, 3, 25, 12, 2, 75, 18 and 3 respectively. Similarly, the Universities portfolio in Phase II, Preclinical and Discovery stages comprises 1, 41 and 7 molecules, respectively.

Amyotrophic Lateral Sclerosis (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Amyotrophic Lateral Sclerosis (Central Nervous System).
  • The pipeline guide reviews pipeline therapeutics for Amyotrophic Lateral Sclerosis (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Amyotrophic Lateral Sclerosis (Central Nervous System) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Amyotrophic Lateral Sclerosis (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Amyotrophic Lateral Sclerosis (Central Nervous System)
REASONS TO BUY
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Amyotrophic Lateral Sclerosis (Central Nervous System).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Amyotrophic Lateral Sclerosis (Central Nervous System) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Introduction
Amyotrophic Lateral Sclerosis - Overview
Amyotrophic Lateral Sclerosis - Therapeutics Development
Amyotrophic Lateral Sclerosis - Therapeutics Assessment
Amyotrophic Lateral Sclerosis - Companies Involved in Therapeutics Development
Amyotrophic Lateral Sclerosis - Drug Profiles
Amyotrophic Lateral Sclerosis - Dormant Projects
Amyotrophic Lateral Sclerosis - Discontinued Products
Amyotrophic Lateral Sclerosis - Product Development Milestones
Appendix

LIST OF TABLES

Number of Products under Development for Amyotrophic Lateral Sclerosis, H2 2017
Number of Products under Development by Companies, H2 2017
Number of Products under Development by Companies, H2 2017 (Contd.1), H2 2017
Number of Products under Development by Companies, H2 2017 (Contd.2), H2 2017
Number of Products under Development by Companies, H2 2017 (Contd.3), H2 2017
Number of Products under Development by Companies, H2 2017 (Contd.4), H2 2017
Number of Products under Development by Companies, H2 2017 (Contd.5), H2 2017
Number of Products under Development by Companies, H2 2017 (Contd.6), H2 2017
Number of Products under Development by Universities/Institutes, H2 2017
Number of Products under Development by Universities/Institutes, H2 2017 (Contd.1), H2 2017
Products under Development by Companies, H2 2017
Products under Development by Companies, H2 2017 (Contd.1), H2 2017
Products under Development by Companies, H2 2017 (Contd.2), H2 2017
Products under Development by Companies, H2 2017 (Contd.3), H2 2017
Products under Development by Companies, H2 2017 (Contd.4), H2 2017
Products under Development by Companies, H2 2017 (Contd.5), H2 2017
Products under Development by Companies, H2 2017 (Contd.6), H2 2017
Products under Development by Companies, H2 2017 (Contd.7), H2 2017
Products under Development by Universities/Institutes, H2 2017
Products under Development by Universities/Institutes, H2 2017 (Contd.1), H2 2017
Products under Development by Universities/Institutes, H2 2017 (Contd.2), H2 2017
Number of Products by Stage and Target, H2 2017
Number of Products by Stage and Target, H2 2017 (Contd.1), H2 2017
Number of Products by Stage and Target, H2 2017 (Contd.2), H2 2017
Number of Products by Stage and Target, H2 2017 (Contd.3), H2 2017
Number of Products by Stage and Target, H2 2017 (Contd.4), H2 2017
Number of Products by Stage and Mechanism of Action, H2 2017
Number of Products by Stage and Mechanism of Action, H2 2017 (Contd.1), H2 2017
Number of Products by Stage and Mechanism of Action, H2 2017 (Contd.2), H2 2017
Number of Products by Stage and Mechanism of Action, H2 2017 (Contd.3), H2 2017
Number of Products by Stage and Mechanism of Action, H2 2017 (Contd.4), H2 2017
Number of Products by Stage and Route of Administration, H2 2017
Number of Products by Stage and Molecule Type, H2 2017
Amyotrophic Lateral Sclerosis - Pipeline by 2-BBB Medicines BV, H2 2017
Amyotrophic Lateral Sclerosis - Pipeline by AB Science SA, H2 2017
Amyotrophic Lateral Sclerosis - Pipeline by Acceleron Pharma Inc, H2 2017
Amyotrophic Lateral Sclerosis - Pipeline by Anavex Life Sciences Corp, H2 2017
Amyotrophic Lateral Sclerosis - Pipeline by Angion Biomedica Corp, H2 2017
Amyotrophic Lateral Sclerosis - Pipeline by Apogenix GmbH, H2 2017
Amyotrophic Lateral Sclerosis - Pipeline by Apotex Inc, H2 2017
Amyotrophic Lateral Sclerosis - Pipeline by ArmaGen Inc, H2 2017
Amyotrophic Lateral Sclerosis - Pipeline by Avanir Pharmaceuticals Inc, H2 2017
Amyotrophic Lateral Sclerosis - Pipeline by AveXis Inc, H2 2017
Amyotrophic Lateral Sclerosis - Pipeline by BioCrea GmbH, H2 2017
Amyotrophic Lateral Sclerosis - Pipeline by BioElectron Technology Corp, H2 2017
Amyotrophic Lateral Sclerosis - Pipeline by Biogen Inc, H2 2017
Amyotrophic Lateral Sclerosis - Pipeline by Biohaven Pharmaceutical Holding Company Ltd, H2 2017
Amyotrophic Lateral Sclerosis - Pipeline by BioHealthonomics Inc, H2 2017
Amyotrophic Lateral Sclerosis - Pipeline by BrainStorm Cell Therapeutics Inc, H2 2017
Amyotrophic Lateral Sclerosis - Pipeline by Catabasis Pharmaceuticals Inc, H2 2017
Amyotrophic Lateral Sclerosis - Pipeline by Chronos Therapeutics Ltd, H2 2017
Amyotrophic Lateral Sclerosis - Pipeline by Chugai Pharmaceutical Co Ltd, H2 2017
Amyotrophic Lateral Sclerosis - Pipeline by Corcept Therapeutics Inc, H2 2017
Amyotrophic Lateral Sclerosis - Pipeline by Corestem Inc, H2 2017
Amyotrophic Lateral Sclerosis - Pipeline by Cytokinetics Inc, H2 2017
Amyotrophic Lateral Sclerosis - Pipeline by Daval International Ltd, H2 2017
Amyotrophic Lateral Sclerosis - Pipeline by Eisai Co Ltd, H2 2017
Amyotrophic Lateral Sclerosis - Pipeline by Ensemble Therapeutics Corp, H2 2017
Amyotrophic Lateral Sclerosis - Pipeline by Evotec AG, H2 2017
Amyotrophic Lateral Sclerosis - Pipeline by Flex Pharma Inc, H2 2017
Amyotrophic Lateral Sclerosis - Pipeline by Gemac SA, H2 2017
Amyotrophic Lateral Sclerosis - Pipeline by Genentech Inc, H2 2017
Amyotrophic Lateral Sclerosis - Pipeline by Genervon Biopharmaceuticals LLC, H2 2017
Amyotrophic Lateral Sclerosis - Pipeline by GeNeuro SA, H2 2017
Amyotrophic Lateral Sclerosis - Pipeline by GenKyoTex SA, H2 2017
Amyotrophic Lateral Sclerosis - Pipeline by Glialogix Inc, H2 2017
Amyotrophic Lateral Sclerosis - Pipeline by Grifols SA, H2 2017
Amyotrophic Lateral Sclerosis - Pipeline by Hemostemix Inc, H2 2017
Amyotrophic Lateral Sclerosis - Pipeline by Herantis Pharma Plc, H2 2017
Amyotrophic Lateral Sclerosis - Pipeline by InFlectis BioScience, H2 2017
Amyotrophic Lateral Sclerosis - Pipeline by Ionis Pharmaceuticals Inc, H2 2017
Amyotrophic Lateral Sclerosis - Pipeline by Italfarmaco SpA, H2 2017
Amyotrophic Lateral Sclerosis - Pipeline by Jeil Pharmaceutical Co Ltd, H2 2017
Amyotrophic Lateral Sclerosis - Pipeline by Kadimastem Ltd, H2 2017
Amyotrophic Lateral Sclerosis - Pipeline by Karyopharm Therapeutics Inc, H2 2017
Amyotrophic Lateral Sclerosis - Pipeline by KineMed Inc, H2 2017
Amyotrophic Lateral Sclerosis - Pipeline by Kringle Pharma Inc, H2 2017
Amyotrophic Lateral Sclerosis - Pipeline by KYORIN Holdings Inc, H2 2017
Amyotrophic Lateral Sclerosis - Pipeline by Kyowa Hakko Kirin Co Ltd, H2 2017
Amyotrophic Lateral Sclerosis - Pipeline by Lead Discovery Center GmbH, H2 2017
Amyotrophic Lateral Sclerosis - Pipeline by M's Science Corp, H2 2017
Amyotrophic Lateral Sclerosis - Pipeline by M3 Biotechnology Inc, H2 2017
Amyotrophic Lateral Sclerosis - Pipeline by Maas Biolab, H2 2017
Amyotrophic Lateral Sclerosis - Pipeline by MallInckrodt Plc, H2 2017
Amyotrophic Lateral Sclerosis - Pipeline by MedDay SA, H2 2017
Amyotrophic Lateral Sclerosis - Pipeline by MimeTech Srl, H2 2017
Amyotrophic Lateral Sclerosis - Pipeline by Miragen Therapeutics Inc, H2 2017
Amyotrophic Lateral Sclerosis - Pipeline by Mitsubishi Tanabe Pharma Corp, H2 2017
Amyotrophic Lateral Sclerosis - Pipeline by Monosol Rx LLC, H2 2017
Amyotrophic Lateral Sclerosis - Pipeline by Neuralstem Inc, H2 2017
Amyotrophic Lateral Sclerosis - Pipeline by Neuraltus Pharmaceuticals Inc, H2 2017
Amyotrophic Lateral Sclerosis - Pipeline by Neurimmune Holding AG, H2 2017
Amyotrophic Lateral Sclerosis - Pipeline by Neurofx Inc, H2 2017
Amyotrophic Lateral Sclerosis - Pipeline by Neurotune AG, H2 2017
Amyotrophic Lateral Sclerosis - Pipeline by Orion Corporation, H2 2017
Amyotrophic Lateral Sclerosis - Pipeline by Orphazyme ApS, H2 2017
Amyotrophic Lateral Sclerosis - Pipeline by Pharnext SA, H2 2017
Amyotrophic Lateral Sclerosis - Pipeline by Plex Pharmaceuticals Inc, H2 2017
Amyotrophic Lateral Sclerosis - Pipeline by Prevacus Inc, H2 2017
Amyotrophic Lateral Sclerosis - Pipeline by ProMIS Neurosciences Inc, H2 2017
Amyotrophic Lateral Sclerosis - Pipeline by Regenesance BV, H2 2017
Amyotrophic Lateral Sclerosis - Pipeline by reMYND NV, H2 2017
Amyotrophic Lateral Sclerosis - Pipeline by SciFluor Life Sciences LLC, H2 2017
Amyotrophic Lateral Sclerosis - Pipeline by Teva Pharmaceutical Industries Ltd, H2 2017
Amyotrophic Lateral Sclerosis - Pipeline by Treeway BV, H2 2017
Amyotrophic Lateral Sclerosis - Pipeline by Valeant Pharmaceuticals International Inc, H2 2017
Amyotrophic Lateral Sclerosis - Pipeline by ViroMed Co Ltd, H2 2017
Amyotrophic Lateral Sclerosis - Pipeline by Voyager Therapeutics Inc, H2 2017
Amyotrophic Lateral Sclerosis - Pipeline by WAVE Life Sciences Ltd, H2 2017
Amyotrophic Lateral Sclerosis - Pipeline by Wilson Therapeutics AB, H2 2017
Amyotrophic Lateral Sclerosis - Pipeline by Yooyoung Pharm Co Ltd, H2 2017
Amyotrophic Lateral Sclerosis - Dormant Projects, H2 2017
Amyotrophic Lateral Sclerosis - Dormant Projects, H2 2017 (Contd.1), H2 2017
Amyotrophic Lateral Sclerosis - Dormant Projects, H2 2017 (Contd.2), H2 2017
Amyotrophic Lateral Sclerosis - Dormant Projects, H2 2017 (Contd.3), H2 2017
Amyotrophic Lateral Sclerosis - Dormant Projects, H2 2017 (Contd.4), H2 2017
Amyotrophic Lateral Sclerosis - Dormant Projects, H2 2017 (Contd.5), H2 2017
Amyotrophic Lateral Sclerosis - Dormant Projects, H2 2017 (Contd.6), H2 2017
Amyotrophic Lateral Sclerosis - Discontinued Products, H2 2017

LIST OF FIGURES

Number of Products under Development for Amyotrophic Lateral Sclerosis, H2 2017
Number of Products under Development by Companies, H2 2017
Number of Products under Development by Universities/Institutes, H2 2017
Number of Products by Top 10 Targets, H2 2017
Number of Products by Stage and Top 10 Targets, H2 2017
Number of Products by Top 10 Mechanism of Actions, H2 2017
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2017
Number of Products by Routes of Administration, H2 2017
Number of Products by Stage and Routes of Administration, H2 2017
Number of Products by Top 10 Molecule Types, H2 2017
Number of Products by Stage and Top 10 Molecule Types, H2 2017

COMPANIES MENTIONED

2-BBB Medicines BV
AB Science SA
Acceleron Pharma Inc
Anavex Life Sciences Corp
Angion Biomedica Corp
Apogenix GmbH
Apotex Inc
ArmaGen Inc
Avanir Pharmaceuticals Inc
AveXis Inc
BioCrea GmbH
BioElectron Technology Corp
Biogen Inc
Biohaven Pharmaceutical Holding Company Ltd
BioHealthonomics Inc
BrainStorm Cell Therapeutics Inc
Catabasis Pharmaceuticals Inc
Chronos Therapeutics Ltd
Chugai Pharmaceutical Co Ltd
Corcept Therapeutics Inc
Corestem Inc
Cytokinetics Inc
Daval International Ltd
Eisai Co Ltd
Ensemble Therapeutics Corp
Evotec AG
Flex Pharma Inc
Gemac SA
Genentech Inc
Genervon Biopharmaceuticals LLC
GeNeuro SA
GenKyoTex SA
Glialogix Inc
Grifols SA
Hemostemix Inc
Herantis Pharma Plc
InFlectis BioScience
Ionis Pharmaceuticals Inc
Italfarmaco SpA
Jeil Pharmaceutical Co Ltd
Kadimastem Ltd
Karyopharm Therapeutics Inc
KineMed Inc
Kringle Pharma Inc
KYORIN Holdings Inc
Kyowa Hakko Kirin Co Ltd
Lead Discovery Center GmbH
M's Science Corp
M3 Biotechnology Inc
Maas Biolab
MallInckrodt Plc
MedDay SA
MimeTech Srl
Miragen Therapeutics Inc
Mitsubishi Tanabe Pharma Corp
Monosol Rx LLC
Neuralstem Inc
Neuraltus Pharmaceuticals Inc
Neurimmune Holding AG
Neurofx Inc
Neurotune AG
Orion Corporation
Orphazyme ApS
Pharnext SA
Plex Pharmaceuticals Inc
Prevacus Inc
ProMIS Neurosciences Inc
Regenesance BV
reMYND NV
SciFluor Life Sciences LLC
Teva Pharmaceutical Industries Ltd
Treeway BV
Valeant Pharmaceuticals International Inc
ViroMed Co Ltd
Voyager Therapeutics Inc
WAVE Life Sciences Ltd
Wilson Therapeutics AB
Yooyoung Pharm Co Ltd
Skip to top


Ask Your Question

Amyotrophic Lateral Sclerosis - Pipeline Review, H2 2017
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: